Be the first person to write a business review for NovaDel Pharma Inc.

Nuvo Research Inc. primarily focuses on the research and development of drug products that are delivered to and through the skin in Canada. It develops drugs based on two technology platforms, transdermal drug delivery and immune system regulation. The company’s lead products include Pennsaid, a topical non-steroidal anti-inflammatory drug, which is used to treat the pain and symptoms of osteoarthritis of the knee; and Pennsaid Plus, a pre clinical stage product used for applications in various therapeutic areas. Nuvo Research Inc. markets its Pennsaid products in Canada and the Caribbean, as well as in European countries, such as Greece, Italy, and the United Kingdom. Its products also comprise Oxoferin, a topical wound healing agent; and WF10, a chlorite-based, immunomodulating drug, which is in the Phase II clinical trial used for the treatment of inoperable pancreatic cancer. It markets its Oxoferin drug in Europe, Asia, and South America under the Oxoferin and Oxovasin trade names.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida. PetMed Express, Inc. (PetMed) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company markets its products through national television, online, and direct mail/print advertising campaigns. PetMed offers a selection of products for dogs, cats, and horses. As of March 31, 2009, its product line contains approximately 750 stock keeping units (skus). These products include brands of medication, such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx and Rimadyl.

Pro-Pharmaceuticals, Inc. is a development-stage company engaged in the discovery and development of carbohydrate-based therapeutics. The Company’s therapeutics is used in treatment of liver, microbial and inflammatory diseases. All of its products were in development, including pre-clinical and clinical trials during the year ended December 31, 2008. The Company focuses on the development of a new generation of anti-cancer treatments using carbohydrate polymers to increase survival and improve the quality of life for cancer patients. Its principal pipeline candidate, DAVANAT, is a chemical entity that is in Phase II trials for first-line treatment of colorectal and biliary cancer. In September 2008, the Company submitted a clinical and pre-clinical package to the United States Food and Drug Administration (FDA) in support of its DAVANAT New Drug Application (NDA).

pSivida Corp. company was founded in 1987 and is based in Watertown, Massachusetts. pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The company's products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.